Immunovant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts CLE development
Bitget2026/09/23 11:06- Immunovant reported topline results from a proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus.
- The study missed its primary goal, prompting Immunovant to halt development of IMVT-1402 in this indication.
- Results showed favorable directional signals on several measures, with stronger antibody reductions linked to better clinical responses.
- Safety and tolerability remained consistent with prior studies, with no new concerns highlighted.
- Other IMVT-1402 development programs remain on schedule across multiple autoimmune diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
